A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, and safety of recombinant human insulin. The study will consist of 2 phases.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Baxter Healthcare Corporation
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Healthy Male Subjects

• Age between 18 and 40 years of age

Exclusion Criteria:

• History of Diabetes

• Subjects with clinically significant active disease

• Known allergy to insulin